The energy metabolism of RIF-1 tumours following hydralazine

Zaver M Bhujwalla, Gillian M. Tozer, Stanley B. Field, Ross J. Maxwell, John R. Grifflths

Research output: Contribution to journalArticle

Abstract

Phosphorus-31 Magnetic Resonance Spectroscopy (MRS) was used to observe the effect of two doses of the vasodilator hydralazine on the energy status of RIF-1 tumours. An intravenous dose of 5 mg/kg hydralazine reduced the high energy phosphate metabolites PCr and ATP, lowered pHMRs and raised the levels of inorganic phosphate of tumours within 20 min of administering the drug. The levels of high energy metabolites continued to decrease for at least 24 h. Normal muscle spectra obtained up to 1 h after drug administration remained unchanged. An intravenous dose of 0.5 mg/kg hydralazine also reduced NTP/Pi and PCr/Pi levels of tumours up to at least 5 h after drug administration, but the effect was smaller than for the higher dose. Blood flow measurements and measurements of systemic blood pressure demonstrated that 5 mg/kg of hydralazine produced a reduction in both systemic blood pressure and tumour blood flow relative to most normal tissues investigated. It is concluded that the changes in the P-31 MRS spectra of tumours were due to a reduction in tumour vascular perfusion following administration of hydralazine.

Original languageEnglish (US)
Pages (from-to)281-291
Number of pages11
JournalRadiotherapy and Oncology
Volume19
Issue number3
DOIs
StatePublished - 1990
Externally publishedYes

Fingerprint

Hydralazine
Energy Metabolism
Neoplasms
Magnetic Resonance Spectroscopy
Phosphates
Pharmaceutical Preparations
Blood Pressure
Vasodilator Agents
Phosphorus
Blood Vessels
Perfusion
Adenosine Triphosphate
Muscles

Keywords

  • Blood flow
  • Blood pressure
  • Energy metabolism
  • Hydralazine
  • P-31 MRS
  • RIF-1 tumour

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Urology

Cite this

The energy metabolism of RIF-1 tumours following hydralazine. / Bhujwalla, Zaver M; Tozer, Gillian M.; Field, Stanley B.; Maxwell, Ross J.; Grifflths, John R.

In: Radiotherapy and Oncology, Vol. 19, No. 3, 1990, p. 281-291.

Research output: Contribution to journalArticle

Bhujwalla, Zaver M ; Tozer, Gillian M. ; Field, Stanley B. ; Maxwell, Ross J. ; Grifflths, John R. / The energy metabolism of RIF-1 tumours following hydralazine. In: Radiotherapy and Oncology. 1990 ; Vol. 19, No. 3. pp. 281-291.
@article{71822f748055444492c6c7bea633cdc0,
title = "The energy metabolism of RIF-1 tumours following hydralazine",
abstract = "Phosphorus-31 Magnetic Resonance Spectroscopy (MRS) was used to observe the effect of two doses of the vasodilator hydralazine on the energy status of RIF-1 tumours. An intravenous dose of 5 mg/kg hydralazine reduced the high energy phosphate metabolites PCr and ATP, lowered pHMRs and raised the levels of inorganic phosphate of tumours within 20 min of administering the drug. The levels of high energy metabolites continued to decrease for at least 24 h. Normal muscle spectra obtained up to 1 h after drug administration remained unchanged. An intravenous dose of 0.5 mg/kg hydralazine also reduced NTP/Pi and PCr/Pi levels of tumours up to at least 5 h after drug administration, but the effect was smaller than for the higher dose. Blood flow measurements and measurements of systemic blood pressure demonstrated that 5 mg/kg of hydralazine produced a reduction in both systemic blood pressure and tumour blood flow relative to most normal tissues investigated. It is concluded that the changes in the P-31 MRS spectra of tumours were due to a reduction in tumour vascular perfusion following administration of hydralazine.",
keywords = "Blood flow, Blood pressure, Energy metabolism, Hydralazine, P-31 MRS, RIF-1 tumour",
author = "Bhujwalla, {Zaver M} and Tozer, {Gillian M.} and Field, {Stanley B.} and Maxwell, {Ross J.} and Grifflths, {John R.}",
year = "1990",
doi = "10.1016/0167-8140(90)90155-P",
language = "English (US)",
volume = "19",
pages = "281--291",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - The energy metabolism of RIF-1 tumours following hydralazine

AU - Bhujwalla, Zaver M

AU - Tozer, Gillian M.

AU - Field, Stanley B.

AU - Maxwell, Ross J.

AU - Grifflths, John R.

PY - 1990

Y1 - 1990

N2 - Phosphorus-31 Magnetic Resonance Spectroscopy (MRS) was used to observe the effect of two doses of the vasodilator hydralazine on the energy status of RIF-1 tumours. An intravenous dose of 5 mg/kg hydralazine reduced the high energy phosphate metabolites PCr and ATP, lowered pHMRs and raised the levels of inorganic phosphate of tumours within 20 min of administering the drug. The levels of high energy metabolites continued to decrease for at least 24 h. Normal muscle spectra obtained up to 1 h after drug administration remained unchanged. An intravenous dose of 0.5 mg/kg hydralazine also reduced NTP/Pi and PCr/Pi levels of tumours up to at least 5 h after drug administration, but the effect was smaller than for the higher dose. Blood flow measurements and measurements of systemic blood pressure demonstrated that 5 mg/kg of hydralazine produced a reduction in both systemic blood pressure and tumour blood flow relative to most normal tissues investigated. It is concluded that the changes in the P-31 MRS spectra of tumours were due to a reduction in tumour vascular perfusion following administration of hydralazine.

AB - Phosphorus-31 Magnetic Resonance Spectroscopy (MRS) was used to observe the effect of two doses of the vasodilator hydralazine on the energy status of RIF-1 tumours. An intravenous dose of 5 mg/kg hydralazine reduced the high energy phosphate metabolites PCr and ATP, lowered pHMRs and raised the levels of inorganic phosphate of tumours within 20 min of administering the drug. The levels of high energy metabolites continued to decrease for at least 24 h. Normal muscle spectra obtained up to 1 h after drug administration remained unchanged. An intravenous dose of 0.5 mg/kg hydralazine also reduced NTP/Pi and PCr/Pi levels of tumours up to at least 5 h after drug administration, but the effect was smaller than for the higher dose. Blood flow measurements and measurements of systemic blood pressure demonstrated that 5 mg/kg of hydralazine produced a reduction in both systemic blood pressure and tumour blood flow relative to most normal tissues investigated. It is concluded that the changes in the P-31 MRS spectra of tumours were due to a reduction in tumour vascular perfusion following administration of hydralazine.

KW - Blood flow

KW - Blood pressure

KW - Energy metabolism

KW - Hydralazine

KW - P-31 MRS

KW - RIF-1 tumour

UR - http://www.scopus.com/inward/record.url?scp=0025146889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025146889&partnerID=8YFLogxK

U2 - 10.1016/0167-8140(90)90155-P

DO - 10.1016/0167-8140(90)90155-P

M3 - Article

VL - 19

SP - 281

EP - 291

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

IS - 3

ER -